New drug combo takes on advanced cancers in first human trial
NCT ID NCT06470763
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests an experimental drug called ANV600, given alone or with the immunotherapy Keytruda, in 240 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the drug can shrink tumors. Because it is a first-in-human trial, the results will help decide if further testing is warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ANV600 (an experimental drug) and pembrolizumab (Keytruda)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This is a very early first-in-human study, so safety and effectiveness are not yet known. Many experimental drugs fail in early trials, and participants may experience side effects without benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CEPCM - AP-HM Hopital de la Timone
Marseille, France
-
Cantonal Hospital St Gallen
Sankt Gallen, Switzerland
-
Charite Universitaetsmedizin Berlin
Berlin, Germany
-
Clinica Universidad de Navarra - Pamplona
Pamplona, Spain
-
Cliniques Universitaires Saint-Luc
Brussels, Belgium
-
Ente Ospedaliero Cantonale - Istituto Oncologico della Svizzera Italiana
Bellinzona, Switzerland
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
INCLIVA Foundation
Valencia, Spain
-
Institut Bergonie
Bordeaux, France
-
Institut Gustave Roussy
Villejuif, France
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Krankenhaus Nordwest - Institut für Klinisch-Onkologische Forschung (IKF)
Frankfurt, Germany
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)
Amsterdam, Netherlands
-
Oncopole Claudius Regaud, Toulouse
Toulouse, France
-
START Madrid CIOCC
Madrid, Spain
-
Universitaetsmedizin der Johannes Gutenberg - Universitaet Mainz
Mainz, Germany
-
Vall d'Hebron Institute of Oncology (VHIO)
Barcelona, Spain